Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

Abstract A recent phase 3 trial showed that outcome of older patients with secondary acute myeloid leukemia (AML) may be improved by a liposomal encapsulation of cytarabine and daunorubicin (CPX‐351). This phase 3 study represents a unique example of prospective data in this rare subgroup providing...

Full description

Bibliographic Details
Main Authors: Sarah Bertoli, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, Eric Delabesse, Thibault Comont, Audrey Sarry, Françoise Huguet, Emilie Bérard, Christian Récher
Format: Article
Language:English
Published: Wiley 2019-07-01
Series:Cancer Medicine
Subjects:
acute myeloid leukemia
azacitidine
CPX‐351
intensive chemotherapy
myelodysplasia‐related changes
secondary AML
Online Access:https://doi.org/10.1002/cam4.2020

Internet

https://doi.org/10.1002/cam4.2020

Similar Items